Cue Competitors
| CUE Stock | USD 0.96 0.01 1.03% |
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Cue Biopharma competition on your existing holdings.
Cue |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Cue Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Cue Biopharma Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Cue Biopharma and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Cue and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Cue Biopharma does not affect the price movement of the other competitor.
| Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Cue Stock performing well and Cue Biopharma Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Cue Biopharma's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| COYA | 3.04 | 0.31 | 0.09 | 0.24 | 3.60 | 7.20 | 20.41 | |||
| LTRN | 4.87 | 0.38 | 0.08 | 0.54 | 4.94 | 12.46 | 44.50 | |||
| FENC | 2.01 | 0.30 | 0.09 | 0.12 | 2.83 | 4.75 | 19.06 | |||
| ELYM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| ANIX | 3.33 | 0.05 | 0.00 | (0.09) | 0.00 | 7.14 | 26.44 | |||
| INMB | 4.67 | 1.06 | 0.21 | 1.03 | 4.50 | 12.57 | 28.67 | |||
| INAB | 5.16 | (0.09) | 0.00 | (0.27) | 0.00 | 11.54 | 32.12 | |||
| PYPD | 4.33 | 0.31 | 0.05 | 0.16 | 5.79 | 10.62 | 41.24 | |||
| XFOR | 7.68 | 0.33 | 0.05 | (3.91) | 7.77 | 26.42 | 68.45 | |||
| GRTX | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Cross Equities Net Income Analysis
Compare Cue Biopharma and related stocks such as Coya Therapeutics, Common, Lantern Pharma, and Fennec Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COYA | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (733.2 K) | (4.9 M) | (14.7 M) | (8 M) | (7.2 M) | (7.5 M) |
| LTRN | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (2.4 M) | (5.9 M) | (12.3 M) | (14.1 M) | (16 M) | (14.4 M) | (13.6 M) |
| FENC | (1.6 M) | 4.7 M | (5.2 M) | 1.8 M | (2.2 M) | (659 K) | (2.8 M) | (7 M) | (9.9 M) | (12.5 M) | (17.9 M) | (17.5 M) | (24.8 M) | (16 M) | (14.4 M) | (13.7 M) |
| ANIX | (1.7 M) | (4.3 M) | (10.1 M) | (9.6 M) | (1.4 M) | (5 M) | (5 M) | (14 M) | (12 M) | (10.1 M) | (12.9 M) | (13.5 M) | (9.8 M) | (12.6 M) | (11.3 M) | (10.7 M) |
| INMB | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (48.9 K) | (277.5 K) | (831.5 K) | (12.4 M) | (9.1 M) | (12.1 M) | (30.3 M) | (28.6 M) | (30 M) | (27 M) | (25.7 M) |
| INAB | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (2.1 M) | (5.1 M) | (8.6 M) | (14.7 M) | (27.4 M) | (30 M) | (27 M) | (25.7 M) |
| PYPD | (1.8 M) | (1.8 M) | (1.8 M) | (3.9 M) | (8.2 M) | (8.2 M) | (11.4 M) | (54.5 M) | 5.9 M | 4.8 M | (35.3 M) | (40.7 M) | (39.5 M) | (23.9 M) | (29 M) | (30.5 M) |
| XFOR | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (13.2 M) | (23 M) | (33.9 M) | (43 M) | (56.6 M) | (62.1 M) | (88.7 M) | (93.9 M) | (101.2 M) | (91.1 M) | (95.6 M) |
| TERN | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (17.7 M) | (68.8 M) | (40.6 M) | (50.2 M) | (60.3 M) | (90.2 M) | (81.2 M) | (85.2 M) |
| DAWN | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (14.7 M) | (40.5 M) | (70.4 M) | (132.2 M) | (188.9 M) | (95.5 M) | (100.3 M) |
| HOOK | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (12.7 M) | (16.2 M) | (34.1 M) | (33.8 M) | (75.7 M) | (65.1 M) | (81.6 M) | (43.5 M) | (45.7 M) |
| CGTX | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (7 M) | (10.1 M) | (10.3 M) | 757 K | (25.8 M) | (23.2 M) | (22 M) |
| TCRX | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (13.1 M) | (26 M) | (48.6 M) | (65.8 M) | (89.2 M) | (127.5 M) | (121.1 M) |
| DRMA | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (5 M) | (3.4 M) | (7.9 M) | (9.6 M) | (7.8 M) | (7 M) | (7.4 M) |
Cue Biopharma and related stocks such as Coya Therapeutics, Common, Lantern Pharma, and Fennec Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Cue Biopharma financial statement analysis. It represents the amount of money remaining after all of Cue Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Cue Biopharma Competitive Analysis
The better you understand Cue Biopharma competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Cue Biopharma's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Cue Biopharma's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Cue Biopharma Competition Performance Charts
Five steps to successful analysis of Cue Biopharma Competition
Cue Biopharma's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Cue Biopharma in relation to its competition. Cue Biopharma's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Cue Biopharma in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Cue Biopharma's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Cue Biopharma, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Cue Biopharma position
In addition to having Cue Biopharma in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Precious Metals Thematic Idea Now
Precious Metals
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Precious Metals theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Precious Metals Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Cue Biopharma Correlation with its peers. For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.You can also try the Top Crypto Exchanges module to search and analyze digital assets across top global cryptocurrency exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.91) | Revenue Per Share | Quarterly Revenue Growth 0.589 | Return On Assets | Return On Equity |
The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.